• Neonatal Medicine
• /
• 제16권2호
• /
• pp.121-130
• /
• 2009

Over the past 20 years, neonatal mortality rates for preterm infants, particularly those born extremely preterm and with a very low birth weight, have decreased steadily. As more very immature preterm infants survive, provision of enteral feeding has become a major focus of concern. According to many experts on neonatal nutrition, the goal for the nutrition of preterm infants should be to achieve a postnatal growth rate approximating that of a normal fetus of the same gestational age. Total parenteral nutrition for maintaining nutritional integrity is mandatory before successful transition to enteral feeding. Early initiation of trophic enteral feeding is vital for postnatal adaptation. Recently published randomized controlled trials provide no evidence to support the practice of postponing enteral feeding to reduce the incidence of necrotizing enterocolitis. Early trophic feeding yields demonstrable benefits and there is currently no evidence of any adverse effects following early feeding. Preterm milk from the infant's own mother is the milk of choice, which can always be supplemented with a human milk fortifier. Here we review over 50 randomized controlled trials and over seven systematic reviews published on neonatal parenteral and enteral feeding of preterm infants. Neonatologists must make use of the evidence from these studies as a reference for feeding protocols for preterm infants in their NICUs are to be based.

• 한국임상약학회지
• /
• 제24권1호
• /
• pp.9-14
• /
• 2014

Background: It is known to reduce the mortality when glutamine is supplied to patients during the surgery or in intensive care unit through intravenous nutrition supply. The purpose of this study is to establish the appropriate basis for use of glutamine and guidelines of nutrition supply for critically ill patients in the hospital by examining the clinical effects of administration of glutamine with subjects of elderly critically ill patients receiving intravenous nutrition in one hospital in Korea. Method: Among elderly patients with age of 60 or more hospitalized in Yeuido St. Mary's Hospital from August 2012 to July 2013, those who stayed in the intensive care unit for more than a week and received TPN (Total Parenteral Nutrition) for more than 3 days during staying in the intensive care unit were classified to a test group using glutamine and a control group without glutamine. Duration of use of mechanical ventilator, duration of hospitalization, occurrence of infectious disease and death were compared between two groups. We would like to identify the clinical test figures affected by the use of glutamine by examining changes in SCr, Total Protein, Albumin, AST, ALT, TB, DB and GFR at the time of admission and discharge. Results: At the time of admission to intensive care unit, gender, physical measurement information and clinical test figures did not show any significant difference between 72 subjects in a test group and 24 subjects in a control group. Thus, two groups began in the same condition. There were no significant difference in duration of hospitalization, duration of intensive care unit, use of mechanical ventilator, occurrence of infectious disease and death. As the results of statistical analysis of the average changes of clinical test figures at the time of admission and discharge of intensive care unit, SCr and GFR were significantly changed in the test group. GFR was significantly changed in a control group. As the result of analysis of the clinical test figures at the time of discharge with reflection of average changes after clinical test figures were corrected at the time of admission of intensive care unit, TB and GFR were significantly increased in a test group compared with those in a control group. Other clinical test figures were not significantly changed. Conclusion: If glutamine is administered to critically ill patients over age 60 receiving TPN and careful monitoring for total bilirubin is made in the future, it is expected to give the positive effect on renal function andminimize the side effect of arise in total bilirubin.

• Nutrition Research and Practice
• /
• 제5권5호
• /
• pp.450-454
• /
• 2011

The beneficial effects of total parenteral nutrition (TPN) in improving the nutritional status of malnourished patients during hospital stays have been well established. However, recent randomized trials and meta-analyses have reported an increased rate of TPN-associated complications and mortality in critically ill patients. The increased risk of complications during TPN therapy has been linked to the development of hyperglycemia, especially during the first few days of TPN therapy. This retrospective study was conducted to determine whether the amount of dextrose from TPN in the 1st week in the intensive care unit (ICU) was related to the development of hyperglycemia and the clinical outcome. We included 88 non-diabetic critically ill patients who stayed in the medical ICU for more than two days. The subjects were 65 ${\pm}$ 16 years old, and the mean APACHE (Acute Physiology and Chronic Health Evaluation) II score upon admission was 20.9${\pm}$7.1. The subjects received 2.3${\pm}$1.4 g/kg/day of dextrose intravenously. We divided the subjects into two groups according to the mean blood glucose (BG) level during the 1st week of ICU stay: <140 mg/dl vs ${\geq}$ 140 mg/dl. Baseline BG and the amount of dextrose delivered via TPN were significantly higher in the hyperglycemia group than those in the normoglycemia group. Mortality was higher in the hyperglycemia group than in the normoglycemia group (42.4% vs 12.8%, P=0.008). The amount of dextrose from TPN was the only significant variable in the multiple linear regression analysis, which included age, APACHE II score, baseline blood glucose concentration and dextrose delivery via TPN as independent variables. We concluded that the amount of dextrose delivered via TPN might be associated with the development of hyperglycemia in critically ill patients without a history of diabetes mellitus. The amount of dextrose in TPN should be decided and adapted carefully to maintain blood glucose within the target range.

• Clinical Nutrition Research
• /
• 제5권2호
• /
• pp.126-136
• /
• 2016

Due to poor nutrition and abnormal energy metabolism, cancer patients typically experience the loss of muscle mass. Although the diabetic conditions or dyslipidemia have been reported as a causal link of cancer but the consequence of such conditions in relation to gain or loss of skeletal muscle mass in cancer patients has not been well documented. The purpose of this study was to investigate the relationship of lean body mass and systemic parameters related to lipid metabolism in non-diabetic cancer patients using data from the Korean National Health and Nutrition Examination Survey (KNHANES) 2008-2011. As results the level of serum total cholesterol (total-C) was negatively associated with both total lean body mass and appendicular lean body mass in cancer patients after adjustment for sex, physical activity, energy intake and comorbidity. The associations between consumption of dietary factors (energy, carbohydrate, protein and fat) and lean body mass were disappeared after adjusting comorbidities of cancer patients. Multivariate-adjusted linear regression analysis by quartiles of serum total-C showed that higher quartile group of total-C had significantly lower percent of lean body mass than reference group in cancer patients. The data indicate that serum lipid status can be the potential estimate of loss of skeletal muscle mass in cancer patients and be referenced in nutrition care of cancer patients under the onset of cachexia or parenteral/enteral nutrition. This data need to be confirmed with large pool of subjects and should be specified by stage of cancer or the site of cancer in future studies.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제5권2호
• /
• pp.174-180
• /
• 2002

목 적: 총정맥영양법의 합병증인 간담도계 장애시 ursodeoxycholic acid (UDCA) 투여는 독성이 있는 내인성 담즙의 분비를 촉진하여 간손상을 감소시키는 역할을 하는 것으로 알려져 있다. 그러나 대부분의 연구는 합병증 발생 후 치료에 관한 것이어서 본 연구자들은 UDCA를 총정맥영양법의 시작과 동시에 조기 투여할 경우 그 예방효과를 이중맹검 위약대조군 연구로써 알아보고자 하였다. 방 법: 2000년 5월부터 2002년 5월까지 10일 이상의 총정맥영양을 받은 13명의 환아를 대상으로 하였다. 총정맥영양 시작과 동시에 UDCA를 투여받는 시험군 7명, 위약을 투여받는 대조군 6명을 이중맹검법으로 구분하였다. 연령은 생후 1일부터 13세까지이고 환아들의 진단은 경관영양이 불가능한 미숙아와 뇌성마비아, 만성설사, 거식증, 췌장염, 주기성 구토증 등이었다. 총정맥영양의 기간은 10일에서 70일까지였다. 주기적으로 간기능을 비롯한 검사항목등을 측정하였으며 총정맥영양의 기간, 조성, 투여속도, 열량 등이 조사 기록되었고 total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase에 대하여 군간 비교하였다. 결 과: Mixed procedure model을 이용한 분석에서 시험군을 reference로 하였을 때 대조군의 autoregressive coefficient 값은 total bilirubin의 경우 0.4419 (p=0.0651), AST는 -0.0431 (p=0.7923), ALT는 0.2398 (p=0.2416), 그리고 alkaline phosphatase는 0.2459 (p=0.1922)였다. 결 론: 총정맥영양과 UDCA를 초기부터 동시 투여하였을 때 total bilirubin은 대조군에 비하여 상승하지 않는 것으로 나타났으나 통계적으로 유의하지는 않았다.

• 한국임상약학회지
• /
• 제15권1호
• /
• pp.9-20
• /
• 2005

Cholestatic liver disease is a frequent complication of prolonged parenteral nutrition, especially in premature infants. Numerous factors have been cited as contributing to TPN associated cholestasis. However the exact etiology remains obscure. Ursodeoxycholic acid (UDCA) has been reported to be beneficial far children and adults with various chronic cholestatic liver disease. The aim of this prospective, randomized, double-blind, placebo-controlled study was to determine the preventive effects of UDCA administration during TPN. Seventeen pediatric patients (8 boys and 9 girls) undergoing TPN were assigned randomly to two groups, UDCA and placebo group. UDCA group (n=9) received 15 mg/kg/day UDCA and placebo group (n=8) received 15 mg/kg/day placebo enterally during the TPN period. Liver function tests (total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase) were per-formed before TPN and weekly or three times a week. The patients' weights, complete blood count, composition of TPN, and the infusion rate of TPN and lipid were monitored everyday. Calcium and phosphate were monitored twice a week. Between the UDCA and placebo groups, there were no differences in weight at the onset of TPN, birth weight, duration of TPN, respiratory distress syndrome associated with prematurity, age at the onset of TPN, gestational age, the number of days the patients received antibiotics, the number of patients received enteral nutritions and the composition of TPN. In contrast, there was a significant difference between the UDCA and placebo groups in alanine aminotransferase levels during TPN. It doesn't seem that UDCA administration during TPN correlates directly with improvement of liver function. But the preventive administration of UDCA may be effective in reducing liver enzyme, alanine aminotransferase and has no adverse effects.

• Clinical and Experimental Pediatrics
• /
• 제49권9호
• /
• pp.972-976
• /
• 2006

목 적 : 극소 저출생 체중아에서 총정맥영양에 의한 담즙정체는 중요한 합병증 중 하나이다. 총정맥영양에 의한 담즙정체에 영양을 미치는 인자들은 여러 가지가 있으며, 그중 아미노산의 조성이 총정맥영양을 시행 받은 극소 저출생 체중아의 담즙정체 발생에 영향을 주는지 알아보고자 하였다. 방 법 : 2000년 1월부터 2004년 12월까지 동아대학교의료원 신생아 중환자실에 입원한 극소 저출생 체중아 중에서 일주일이상 총정맥영양을 시행 받은 환아 63명을 연구대상으로 하였다. 2000년 1월부터 2002년 6월까지의 연구 대상을 제1군으로, 2002년 7월부터 2004년 12월까지의 연구대상은 제1군과는 cysteine, tyrosine, taurine, glutamate 등의 성분이 차이가 있는 아미노산 제제를 사용하여 제2군으로 분류하였다. 제1군과 제2군의 임상적 특징과 총정맥영양에 의한 담즙정체의 빈도를 비교하였다. 결 과 : 제1군(n=32)과 제2군(n=31)의 재태연령($29.7{\pm}2.7$주, $29.5{\pm}2.8$주), 출생체중($1,195.6{\pm}200.4g$, $1,177.0{\pm}224.0g$) 및 총정맥영양 시작시기($16.1{\pm}8.5$일, $14.8{\pm}7.7$일), 총정맥영양의 기간($25.7{\pm}13.5$일, $25.4{\pm}12.1$일), 제공된 아미노산의 양($1.45{\pm}0.49$g/kg/일, $1.65{\pm}0.89$ g/kg/일), 완전장관영양 도달시기($59.9{\pm}23.2$일, $61.0{\pm}18.0$ 일)에는 유의한 차이가 없었다. 총정맥영양과 관련된 담즙정체의 빈도는 제1군은 7례(21.9%), 제2군은 2례(6.5 %)로 제2군에서 감소되는 경향을 보였으나 통계학적 의미는 없었다(P=0.148). 두 군 간의 최고 직접 빌리루빈 수치($1.62{\pm}1.18mg/dL$, $1.04{\pm}1.05mg/dL$, P=0.046)와 평균 직접 빌리루빈 수치($0.78{\pm}0.46mg/dL$, $0.52{\pm}0.29mg/dL$, P=0.012)는 각각 제2군에서 의미 있게 낮았다. 결 론 : 총정맥영양을 시행 받은 극소 저출생 체중아에서 생기는 총정맥영양에 관련된 담즙정체를 비교한 결과, 아미노산 조성의 차이에 따라 담즙정체의 발생 빈도에 차이가 있었으나 통계학적 유의성은 없었고, 직접 빌리루빈 수치는 의미 있게 감소하였다. 그러나 좀 더 많은 연구 대상을 통한 연구가 필요하리라 생각한다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제12권1호
• /
• pp.39-45
• /
• 2009

목 적: 영양지원팀(nutritional support team, NST)은 영양부족이 위험성이 있는 환자에게 영양을 효율적으로 제공하기 위해 운영된다. 미숙아는 소화, 흡수의 미숙, 비축된 영양의 부족, 요구량의 증가, 다양한 질환에의 이환으로 인하여 영양 불균형의 위험성이 높으며 경구영양이 완전히 진행되기까지는 총정맥영양(total parenteral nutrition, TPN)에 의존하므로 적극적인 영양지원을 필요로 한다. 이에 본 연구에서는 NST 활동이 신생아중환자실에 입원하여 TPN을 투여 받는 미숙아들의 임상경과에 미치는 영향을 검토함으로써 NST의 임상적 의의를 평가하고자 하였다. 방 법: 2003년 7월에서 2006년 7월까지 분당서울대 병원 신생아중환자실에 입원하여 TPN을 시행 받은 미숙아 48명을 대상으로 하여 후향적으로 의무기록을 검토하였다. 대상 환아들을 NST 활동 여부에 따라 각각 NST 설립 이전 시기인 2003년 7월에서 2005년 2월까지 입원한 미숙아군과 NST 활동 시기인 2005년 3월에서 2006년 7월 사이에 입원한 미숙아군으로 나누어 각 군에서의 임상 지표들을 비교분석하여 NST 활동이 미치는 영향을 평가하였다. 통계학적 분석을 위해 Mann-Whitney 검정과 Fisher's exact test를 적용하였고, pvalue 0.05 미만을 통계적으로 유의하다고 판정하였다. 결 과: 대상 환아 48명(남아 27명, 여아 21명)의 재태기간은 평균 $28^{+1}$주(범위: 25주~$32^{+6}$주), 출생체중은 평균 1,008.5${\pm}$242.5 g (범위: 520~1,490 g), 재원기간은 평균 74${\pm}$40일(범위: 26~274일)이었다. 영양사, 약사 또는 NST가 환아의 TPN에 개입하기까지의 기간이 NST 활동 전에는 14.8${\pm}$21.0일 소요되었으나 NST 활동 이후 0.5${\pm}$2.0일로 유의하게 감소하였다(p=0.000). TPN 투여기간은 NST 활동 전의 41.5${\pm}$26.2일에서 NST 활동 후에는 20.5${\pm}$16.6일로 유의하게 감소하였다(p=0.001). TPN을 통해 투여된 칼로리는 NST 활동 전후로 각각 88.1${\pm}$19.0 kcal/kg/day와 98.8${\pm}$8.2 kcal/kg/day로서 유의하게 상승하였고(p=0.016), 단백 투여량은 각각 2.74${\pm}$0.50 g/kg/day와 3.36 g/kg${\pm}$0.34 g/kg/day (p=0.000), 지방 투여량은 각각 2.53${\pm}$0.86 g/kg/day와 3.40 g/kg${\pm}$0.52 g/kg/day로서 두 군 간에 유의한 차이를 보였다(p=0.000). 환아들의 금식기간이 NST 활동 전후 각각 10.5${\pm}$11.3일과 5.9${\pm}$7.3일로서 NST 활동 시작 후 유의하게 감소하였으며(p=0.017), 환자들이 완전 경장영양으로 진행하기까지 소요된 기간도 각각 44.7${\pm}$26.1일과 24.0${\pm}$17.6일로 NST 활동 후 의미 있게 감소하였다 (p=0.001). 항생제 투여기간도 NST 활동 전의 34.8${\pm}$30.8일에서 NST 활동과 더불어 15.6${\pm}$15.2일로 유의하게 감소하였다(p=0.007). 결 론: 신생아중환자실에 입원한 미숙아에게 있어 NST 활동에 의한 적극적인 영양지원은 적절한 영양을 공급하여 영양상태를 개선하는 측면과 더불어 임상적 측면에서도 장점이 있으므로 미숙아의 영양지원에 있어 NST 활동이 갖는 의의가 크다고 하겠다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제20권1호
• /
• pp.55-60
• /
• 2017

Intestinal hypoganglionosis is a rare innervation disorder that provides numerous nutritional, medical and surgical challenges. In this case report, we present a case of a newborn with intestinal hypoganglionosis leading to intestinal failure and intestinal failure-associated liver disease who responded to $Omegaven^{TM}$, a fat emulsion comprised of omega-3 fatty acids. $Omegaven^{TM}$ has been shown to be beneficial in the management of cholestatic liver injury. Clinical success with $Omegaven^{TM}$ was seen in this patient with a clear decrease in aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and complete resolution of cholestasis with a direct bilirubin of zero within two weeks of initiation of $Omegaven^{TM}$. No current guidelines for the diagnosis and management of hypoganglionosis are available. We recommend a multidisciplinary approach and the use of novel therapies such as fat emulsions composed of omega-3 fatty acids for improved patient outcomes. Appropriate compassionate use protocols should be obtained from the Food and Drug Administration prior to initiation of $Omegaven^{TM}$.

• 한국임상약학회지
• /
• 제23권4호
• /
• pp.365-372
• /
• 2013

Background: Malnutrition of inpatients has been associated with higher morbidity, mortality, cost, and longer hospital stay. Total parenteral nutrition (TPN) therapy plays an important role in decreasing morbidity and mortality among critical inpatients in hospitals, and has been commonly used to improve clinical outcomes. However, only a few studies were conducted regarding patients' nutritional improvement by TPN. Method: This study therefore evaluated the changes in nutritional parameters by TPN therapy for early malnourished inpatients. Data from early malnourished inpatients who were treated with TPN therapy between January 2012 and June 2013 at the ${\bigcirc}{\bigcirc}$ university Hospital were studied retrospectively. Information regarding sex, age, underlying diseases, division, TPN (peripheral and central), and changes in nutritional parameters were collected by reviewing electronic medical records. The criteria for evaluation of the changes in nutritional parameters were included physical marker, body mass index (BMI), and biochemical markers, including albumin (Alb), total lymphocyte count (TLC), and cholesterol. Nutritional parameters were collected three times: pre-TPN, mid-TPN and end-TPN. A total of 149 patients (peripheral, 97; central, 52) was evaluated. Results: In all patients, the malnutrition number was significantly decreased following the complete TPN therapy (peripheral patients, pre-TPN: $3.33{\pm}0.12$, mid-TPN : $3.06{\pm}0.17$, and end-TPN: $2.85{\pm}0.21$ (p < 0.05); central patients, pre-TPN: $3.38{\pm}0.11$, mid-TPN: $3.06{\pm}0.13$, and end-TPN: $2.75{\pm}0.21$ (p < 0.05). The malnutrition number means number of nutrition parameters below normal range of malnutrition. In addition, all of the four nutritional parameters (BMI, Alb, TLC and cholesterol) were increased with duration of TPN periods for all patients, and the changes in the early stage were larger than in the late stage (p < 0.05). The nutritional parameters of non-cancer patients were increased to a greater extent compared to cancer patients with longer TPN therapy, but it was not significant. The nutritional parameters of younger patients (50-60 years) were also increased more than of older patients (70-80 years), but it was not significant. Conclusion: In conclusion, the TPN therapy decreases malnutritional status and improves nutritional parameters in malnourished patients, thereby decreasing morbidity and mortality. The combined evaluation of all four nutritional parameters is more accurate for nutritional assessment than a single one.